QualityStocks would like to highlight IGI Laboratories (NYSE: IG), a specialty manufacturing company specializing in topical products, and offering a full range of services: formulation and methods development, analytical support, scale-up, commercial manufacturing and packaging. IGI is uniquely positioned as an integrated formulation manufacturing company, providing services to the pharmaceutical, cosmetic, and cosmeceutical industries, as both a contract development organization and a contract manufacturing provider. The company's services are adaptable, from formulation work only, to bulk manufacturing or full turnkey production.
In the company’s news yesterday,
IGI Laboratories announced it will launch its first IGI labeled generic products later this year.
The company has an extensive partnership with Medimetriks Pharmaceuticals, Inc., which is a branded specialty pharmaceutical company focused on the dermatology market. As part of this relationship, IGI serves as Medimetriks’ authorized generic dealer for certain products. On Nov. 1, IGI received authorization to launch generic distribution of certain of Medimetriks’ recently launched Synalar (fluocinolone acetonide) line of prescription topical products.
IGI will work closely with Medimetriks to help ensure the successful launch of these generic topical prescription products. IGI believes this launch with its important partner is an essential component of the company’s long-term strategy. The current market conditions indicate a total addressable market for the first three products of around $30 million, of which IGI expects to achieve a meaningful market share.
Launch activity has commenced, and with the authorization to go to market, only a few steps remain before the company’s first IGI labeled generic topical product is ready to launch. The company has made significant strides in finalizing the needful state licensing requirements for commercial distribution. IGI is actively negotiating its logistics agreements with the proper wholesalers and retailers, and the company additionally plans to announce its distribution partner in the near future.
The pivot discussed in IGI’s last earnings call is well underway. With this launch, the company is in motion to deliver on its promise to become a leader in the generic topical pharmaceutical market.
IGI Laboratories is engaged in the development and manufacturing of topical formulations for the pharmaceutical, OTC, and cosmetic markets. The company’s aim is to become a leading player in the generic topical prescription drug market.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
